DIRECT ORAL ANTICOAGULANTS IN PATIENTS AFFECTED BY MAJOR CONGENITAL THROMBOPHILIA
| Autor: | Alessandra Serrao, Cristina Santoro, Robin Foà, Antonietta Ferretti, Benedetta Lucani, Antonio Chistolini, Davide Mansour, Erminia Baldacci |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class Deep vein 030204 cardiovascular system & hematology Thrombophilia Gastroenterology 03 medical and health sciences Key words: direct oral anticoagulants thrombophilia thromboembolism venous thrombosis 0302 clinical medicine Protein C and S deficiency Internal medicine medicine Factor V Leiden 030212 general & internal medicine Protein S deficiency cardiovascular diseases Antithrombin-III Direct oral anticoagulant Familial thrombophilia Vitamin K antagonist business.industry lcsh:RC633-647.5 Antithrombin Hematology lcsh:Diseases of the blood and blood-forming organs medicine.disease Thrombosis Infectious Diseases medicine.anatomical_structure Original Article business Protein C medicine.drug |
| Zdroj: | Mediterranean Journal of Hematology and Infectious Diseases, Vol 11, Iss 1 (2019) Mediterranean Journal of Hematology and Infectious Diseases |
| ISSN: | 2035-3006 |
| Popis: | Introduction: Thrombophilia is a condition that predisposes to a higher incidence of venous thromboembolisms (VTE), some also in atypical sites. Direct oral anticoagulants (DOACs) have proven to be effective in the treatment of deep vein thrombosis (DVT). However, their use can be sometimes challenging in particular settings of patients such as those with major thrombophilia - antithrombin, protein C and protein S deficiency, homozygous mutation of Factor V Leiden, homozygous mutation of Factor II G20210A, combined heterozygous mutation of factor V Leiden and Factor II G20210A – carrying a high thrombotic risk. Patients and methods: At our Center, 45 patients with major thrombophilia were treated with DOACs: 33 after an initial treatment with vitamin K antagonists (VKA) and 12 as first line therapy for VTE. The median follow-up of DOACs treatment was 29 months. Conclusions: No patient presented hemorrhagic or thrombotic complications during DOAC therapy. DOACs have proven to be effective and safe in this real-life series of patients with major thrombophilia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|